Global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results

Treatment options for chronic thromboembolic pulmonary hypertension (CTEPH) are rapidly expanding. The purpose of this study is to identify trends in CTEPH clinical trials and the publication of results. We performed a worldwide review of completed and ongoing clinical trials through searching the C...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Micheal C. McInnis, Clement T. Chow, Alexandre Boutet, Sebastian Mafeld, John Granton, Karen McRae, Laura Donahoe, Marc de Perrot
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701 Diseases of the respiratory system RC705-779
Acceso en línea:	https://doaj.org/article/d8ea23c21ea04e3d8d4b51788b6598c9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d8ea23c21ea04e3d8d4b51788b6598c9
record_format	dspace
spelling	oai:doaj.org-article:d8ea23c21ea04e3d8d4b51788b6598c92021-11-18T23:34:54ZGlobal trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results2045-894010.1177/20458940211059994https://doaj.org/article/d8ea23c21ea04e3d8d4b51788b6598c92021-11-01T00:00:00Zhttps://doi.org/10.1177/20458940211059994https://doaj.org/toc/2045-8940Treatment options for chronic thromboembolic pulmonary hypertension (CTEPH) are rapidly expanding. The purpose of this study is to identify trends in CTEPH clinical trials and the publication of results. We performed a worldwide review of completed and ongoing clinical trials through searching the ClinicalTrials.gov database and the World Health Organization International Clinical Trials Registry Platform for “CTEPH” and related terms. Entries were classified as pharmaceutical/procedural interventions (Group 1), all other clinical trials (Group 2) and patient registries (Group 3). Trial characteristics and national affiliation were recorded. PubMed was searched for related publications. There were 117 clinical trials registry entries after removing duplicates and non-target records. Group 1 comprised 29 pharmaceutical, 15 procedural, and four combined interventions starting in 2005, 2010, and 2016, respectively. Riociguat and balloon pulmonary angioplasty were the most frequent pharmaceutical and procedural interventions, respectively. The proportion of procedural trials increased over time from 0% of those in 2005–2009 to 29% in 2010–2014 and 54% in 2015–2020. There were 56 entries in Group 2 and 13 in Group 3. Japan was the most frequent national affiliation and the most frequent participating country, present in 28% of all trials. The proportion of entries with published results was highest with Group 3 (62%) and lowest with Group 1 (27%). Thirty percent of all publications occurred in 2020. In conclusion, CTEPH clinical trials are increasingly procedural based, with growth largely attributable to Japan and balloon pulmonary angioplasty. Most trials have not published, but results from balloon pulmonary angioplasty clinical trials are anticipated soon.Micheal C. McInnisClement T. ChowAlexandre BoutetSebastian MafeldJohn GrantonKaren McRaeLaura DonahoeMarc de PerrotSAGE PublishingarticleDiseases of the circulatory (Cardiovascular) systemRC666-701Diseases of the respiratory systemRC705-779ENPulmonary Circulation, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701 Diseases of the respiratory system RC705-779
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Diseases of the respiratory system RC705-779 Micheal C. McInnis Clement T. Chow Alexandre Boutet Sebastian Mafeld John Granton Karen McRae Laura Donahoe Marc de Perrot Global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results
description	Treatment options for chronic thromboembolic pulmonary hypertension (CTEPH) are rapidly expanding. The purpose of this study is to identify trends in CTEPH clinical trials and the publication of results. We performed a worldwide review of completed and ongoing clinical trials through searching the ClinicalTrials.gov database and the World Health Organization International Clinical Trials Registry Platform for “CTEPH” and related terms. Entries were classified as pharmaceutical/procedural interventions (Group 1), all other clinical trials (Group 2) and patient registries (Group 3). Trial characteristics and national affiliation were recorded. PubMed was searched for related publications. There were 117 clinical trials registry entries after removing duplicates and non-target records. Group 1 comprised 29 pharmaceutical, 15 procedural, and four combined interventions starting in 2005, 2010, and 2016, respectively. Riociguat and balloon pulmonary angioplasty were the most frequent pharmaceutical and procedural interventions, respectively. The proportion of procedural trials increased over time from 0% of those in 2005–2009 to 29% in 2010–2014 and 54% in 2015–2020. There were 56 entries in Group 2 and 13 in Group 3. Japan was the most frequent national affiliation and the most frequent participating country, present in 28% of all trials. The proportion of entries with published results was highest with Group 3 (62%) and lowest with Group 1 (27%). Thirty percent of all publications occurred in 2020. In conclusion, CTEPH clinical trials are increasingly procedural based, with growth largely attributable to Japan and balloon pulmonary angioplasty. Most trials have not published, but results from balloon pulmonary angioplasty clinical trials are anticipated soon.
format	article
author	Micheal C. McInnis Clement T. Chow Alexandre Boutet Sebastian Mafeld John Granton Karen McRae Laura Donahoe Marc de Perrot
author_facet	Micheal C. McInnis Clement T. Chow Alexandre Boutet Sebastian Mafeld John Granton Karen McRae Laura Donahoe Marc de Perrot
author_sort	Micheal C. McInnis
title	Global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results
title_short	Global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results
title_full	Global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results
title_fullStr	Global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results
title_full_unstemmed	Global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results
title_sort	global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/d8ea23c21ea04e3d8d4b51788b6598c9
work_keys_str_mv	AT michealcmcinnis globaltrendsinchronicthromboembolicpulmonaryhypertensionclinicaltrialsanddisseminationofresults AT clementtchow globaltrendsinchronicthromboembolicpulmonaryhypertensionclinicaltrialsanddisseminationofresults AT alexandreboutet globaltrendsinchronicthromboembolicpulmonaryhypertensionclinicaltrialsanddisseminationofresults AT sebastianmafeld globaltrendsinchronicthromboembolicpulmonaryhypertensionclinicaltrialsanddisseminationofresults AT johngranton globaltrendsinchronicthromboembolicpulmonaryhypertensionclinicaltrialsanddisseminationofresults AT karenmcrae globaltrendsinchronicthromboembolicpulmonaryhypertensionclinicaltrialsanddisseminationofresults AT lauradonahoe globaltrendsinchronicthromboembolicpulmonaryhypertensionclinicaltrialsanddisseminationofresults AT marcdeperrot globaltrendsinchronicthromboembolicpulmonaryhypertensionclinicaltrialsanddisseminationofresults
_version_	1718420697998426112

Global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results

Ejemplares similares